Evidence map›Paper›PMID 35582674›Full record

ReviewWorld journal of gastroenterology2022

Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges.

Nicola Pugliese, Ivan Arcari, Alessio Aghemo, Andrea G Lania, Ana Lleo, Gherardo Mazziotti

Open access · hybridAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Sarcopenia-A Valuable Imaging Biomarker for Disease Progression in Patients With Primary Sclerosing Cholangitis (PSC)?Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Nicola PuglieseDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy.
Ivan ArcariDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy.
Alessio AghemoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy.
Andrea G LaniaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy.
Ana LleoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy.
Gherardo MazziottiDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy.
Humanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary biliary cholangitis and primary sclerosing cholangitis (PSC) are the most common cholestatic liver diseases (CLD) in adults and are both characterized by an immune pathogenesis. While primary biliary cholangitis is a model autoimmune disease, with over 90% of patients presenting very specific autoantibodies against mitochondrial antigens, PSC is considered an immune mediated disease. Osteoporosis is the most common bone disease in CLD, resulting in frequent fractures and leading to significant morbidity. Further, sarcopenia is emerging as a frequent complication of chronic liver diseases with a significant prognostic impact and severe implications on the quality of life of patients. The mechanisms underlying osteoporosis and sarcopenia in CLD are still largely unknown and the association between these clinical conditions remains to be dissected. Although timely diagnosis, prevention, and management of osteosarcopenia are crucial to limit the consequences, there are no specific guidelines for management of osteoporosis and sarcopenia in patients with CLD. International guidelines recommend screening for bone disease at the time of diagnosis of CLD. However, the optimal monitoring strategies and treatments have not been defined yet and vary among centers. We herein aim to comprehensively outline the pathogenic mechanisms and clinical implications of osteosarcopenia in CLD, and to summarize expert recommendations for appropriate diagnostic and therapeutic approaches.

Indexed as

Autoimmune DiseasesCholangitis, SclerosingCholestasisLiver Cirrhosis, BiliaryLiver DiseasesOsteoporosisSarcopeniaAdultHumansQuality of LifeCholestatic liver diseasesOsteoporosisPrimary biliary cholangitisPrimary sclerosing cholangitisSarcopenia

Identifiers

PMID35582674
PMCPMC9048470
OpenAlexW4226133099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.